What drove the pre-market move in 42C.SI stock today?

Pre-market moves follow the earnings announcement dated 2026-02-09, elevated volume of **28,976,800**, and investor focus on EPS **-0.01** and cash flow. Clinical pipeline updates and management comments amplified volatility.

What is Meyka AI's price forecast for 42C.SI stock?

Meyka AI's forecast model projects **monthly S$0.25**, **quarterly S$0.34**, and **12-month S$0.85329**. These are model outputs and not guarantees; they guide scenario planning.

How does iX Biopharma's valuation compare with peers for 42C.SI stock?

Valuation is high by peers with **price-to-sales 24.71** and **price-to-book 483.02**, reflecting clinical optionality rather than current cash earnings. That elevates execution risk relative to sector averages.

Should dividend prospects affect an investment in 42C.SI stock?

iX Biopharma currently has no dividend yield reported. Given negative free cash flow per share, dividend prospects are remote until cash flow improves or a strategic shift occurs.

SG Stocks

iX Biopharma (42C.SI, SES) S$0.19 pre-market 10 Feb 2026: Model flags upside

ByHuzaifa Zahoor February 10, 2026February 10, 2026

We start pre-market with iX Biopharma (42C.SI) trading at S$0.192 after an earnings update tied to a 2026-02-09 announcement. The short-term move came on 28,976,800 shares traded and a -4.00% one-day change. Investors want clarity on cash flow, clinical progress, and near-term revenue recognition. We use the earnings detail to show how clinical milestones and volume swings could drive the next price moves in the Singapore (SES) market.